EUVIMEDEUVIMED entdecken
Crossref

Impact of 18 F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer

Jeongryul Ryu, Jaewon Hyung, Sangwon Han, Jae Ho Jeong, Sae Byul Lee, Tae-Kyung Robyn Yoo, Jisun Kim, Hee Jeong Kim, Il Yong Chung, Beom Seok Ko, Jong Won Lee, Byung Ho Son und 5 weitere

Journal of Nuclear Medicine · 2024-11 · 65 (11) · 1689-1694

DOI: 10.2967/jnumed.124.267913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.10.2024. Verfasst von Jeongryul Ryu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron Emission Tomography Computed Tomography, Neoplasm Metastasis, Estradiol. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical impact of 16α-18F-fluoro-17β-estradiol (18F-FES) PET/CT on patient management has not been well investigated. The aim of this study was to assess the clinical impact of 18F-FES PET/CT on the management of patients with recurrent or metastatic breast cancer.

Methods

Study subjects were identified retrospectively from a database of a prospective trial for postmarketing surveillance of 18F-FES between 2021 and 2023. Patients who were suspected or known to have recurrent or metastatic estrogen receptor-positive breast cancer based on a routine standard workup were included. Planned management before and actual management after 18F-FES PET/CT were assessed by 2 experienced medical oncologists via medical chart review. A 5-point questionnaire was provided to evaluate the value of 18F-FES PET/CT for management planning. The rate of intention-to-treat and interdisciplinary changes, and the impact of 18F-FES PET/CT according to PET/CT result or clinical indication, were examined.

Results

Of the 344 included patients, 120 (35%) experienced a change in management after 18F-FES PET/CT. In 139 (40%) patients,18F-FES PET/CT supported the existing management decision without a change in management. Intention-to-treat and interdisciplinary changes accounted for 64% (77/120) and 68% (82/120) of all changes, respectively. A higher rate of change was observed when lesions were 18F-FES-negative (44% [36/81]) than 18F-FES-positive (30% [51/172]) or mixed 18F-FES-positive/negative (36% [33/91]). Regarding clinical indications, the highest rate of change was shown when evaluating the origins of metastasis of double primary cancers (64% [9/14]).

Conclusion

18F-FES PET/CT modified the management of recurrent or metastatic breast cancer, serving as an impactful imaging modality in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPositron Emission Tomography Computed TomographyNeoplasm MetastasisEstradiolHumansFemaleMiddle AgedAgedRetrospective StudiesClinical Decision-MakingAdultNeoplasm Recurrence, LocalRecurrence

Stichwörter der Autor:innen

18F-FES PETbreast cancerestrogen receptorimpactstandard imaging

Substanzen

Estradiol16-fluoroestradiol

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; and.
  • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; hswon87@naver.com jaeho.jeong@amc.seoul.kr.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; and hswon87@naver.com jaeho.jeong@amc.seoul.kr.
  • Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Zitieren

APA

Ryu, J., Hyung, J., Han, S., Jeong, J. H., Lee, S. B., Yoo, T. R., Kim, J., Kim, H. J., Chung, I. Y., Ko, B. S., Lee, J. W., Son, B. H., Jeong, H., Ahn, J. H., Jung, K. H., Kim, S. B., & Moon, D. H. (2024). Impact of 18 F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer. Journal of Nuclear Medicine, 65(11), 1689-1694. https://doi.org/10.2967/jnumed.124.267913

Vancouver

Ryu J, Hyung J, Han S, Jeong JH, Lee SB, Yoo TR, et al. Impact of 18 F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer. Journal of Nuclear Medicine. 2024;65(11):1689-1694. doi:10.2967/jnumed.124.267913

BibTeX
@article{Ryu2024,
  author = {Ryu, Jeongryul and Hyung, Jaewon and Han, Sangwon and Jeong, Jae Ho and Lee, Sae Byul and Yoo, Tae-Kyung Robyn and Kim, Jisun and Kim, Hee Jeong and Chung, Il Yong and Ko, Beom Seok and Lee, Jong Won and Son, Byung Ho and Jeong, Hyehyun and Ahn, Jin-Hee and Jung, Kyung Hae and Kim, Sung-Bae and Moon, Dae Hyuk},
  title = {Impact of 18 F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {11},
  pages = {1689--1694},
  doi = {10.2967/jnumed.124.267913}
}
Kostenlos starten →